No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CSBR Champions Oncology
- 4.900
- -0.150-2.97%
Trading Jul 23 14:16 ET
66.61MMarket Cap-9074P/E (TTM)
5.000High4.900Low1.45KVolume5.040Open5.050Pre Close7.17KTurnover0.03%Turnover RatioLossP/E (Static)13.59MShares7.13052wk High-35.00P/B23.28MFloat Cap4.50052wk Low--Dividend TTM4.75MShs Float25.800Historical High--Div YieldTTM1.98%Amplitude0.072Historical Low4.930Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Champions Oncology | 10-K: Annual report
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating, Announces Target Price $6
Earnings Call Summary | Champions Oncology(CSBR.US) Q4 2024 Earnings Conference
Champions Oncology, Inc. (CSBR) Q4 2024 Earnings Call Transcript
Champions Oncology Q4 2024 Adj EPS $0.01 Beats $(0.16) Estimate, Sales $14.001M Beat $12.692M Estimate
Earnings Flash (CSBR) CHAMPIONS ONCOLOGY Posts Q4 EPS $0.01
Comments
$Champions Oncology(CSBR.US$
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024.
Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000.
However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million.
The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending p...
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024.
Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000.
However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million.
The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending p...
$Champions Oncology(CSBR.US$
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims...
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg